PL3260136T3 - Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) - Google Patents
Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)Info
- Publication number
- PL3260136T3 PL3260136T3 PL17173548T PL17173548T PL3260136T3 PL 3260136 T3 PL3260136 T3 PL 3260136T3 PL 17173548 T PL17173548 T PL 17173548T PL 17173548 T PL17173548 T PL 17173548T PL 3260136 T3 PL3260136 T3 PL 3260136T3
- Authority
- PL
- Poland
- Prior art keywords
- hiv
- immunodeficiency virus
- human immunodeficiency
- neutralizing antibodies
- neutralizing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- AIDS & HIV (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16101009P | 2009-03-17 | 2009-03-17 | |
| US16582909P | 2009-04-01 | 2009-04-01 | |
| US22473909P | 2009-07-10 | 2009-07-10 | |
| US28566409P | 2009-12-11 | 2009-12-11 | |
| EP10722810.8A EP2408476B1 (en) | 2009-03-17 | 2010-03-17 | Human immunodeficiency virus (hiv) -neutralizing antibodies |
| EP17173548.3A EP3260136B1 (en) | 2009-03-17 | 2010-03-17 | Human immunodeficiency virus (hiv) -neutralizing antibodies |
| PCT/US2010/027695 WO2010107939A2 (en) | 2009-03-17 | 2010-03-17 | Human immunodeficiency virus (hiv) -neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3260136T3 true PL3260136T3 (pl) | 2021-10-18 |
Family
ID=42668183
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17194834T PL3323427T3 (pl) | 2009-03-17 | 2010-03-17 | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) |
| PL10722810T PL2408476T3 (pl) | 2009-03-17 | 2010-03-17 | Przeciwciała neutralizujące ludzkiego wirusa niedoboru odporności (HIV) |
| PL17173548T PL3260136T3 (pl) | 2009-03-17 | 2010-03-17 | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) |
| PL18207707.3T PL3542817T3 (pl) | 2009-03-17 | 2010-03-17 | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17194834T PL3323427T3 (pl) | 2009-03-17 | 2010-03-17 | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) |
| PL10722810T PL2408476T3 (pl) | 2009-03-17 | 2010-03-17 | Przeciwciała neutralizujące ludzkiego wirusa niedoboru odporności (HIV) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18207707.3T PL3542817T3 (pl) | 2009-03-17 | 2010-03-17 | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US9051362B2 (pl) |
| EP (5) | EP3542817B1 (pl) |
| AU (5) | AU2010226668B2 (pl) |
| CA (2) | CA2980883C (pl) |
| CY (1) | CY1121323T1 (pl) |
| DK (1) | DK2408476T3 (pl) |
| ES (4) | ES2848555T3 (pl) |
| HR (1) | HRP20180027T1 (pl) |
| HU (1) | HUE036031T2 (pl) |
| LT (1) | LT2408476T (pl) |
| NO (1) | NO2408476T3 (pl) |
| PL (4) | PL3323427T3 (pl) |
| PT (4) | PT3542817T (pl) |
| SI (4) | SI3260136T1 (pl) |
| SM (1) | SMT201800016T1 (pl) |
| WO (1) | WO2010107939A2 (pl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| US20110212106A1 (en) * | 2010-01-20 | 2011-09-01 | Institute For Research In Bioscience | Hiv-1 neutralizing antibodies and uses thereof |
| US8586056B2 (en) * | 2010-03-02 | 2013-11-19 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
| CA3201524C (en) | 2010-08-31 | 2026-01-13 | International Aids Vaccine Initiative | Human immunodeficiency virus (hiv)-neutralizing antibodies |
| WO2012040562A2 (en) | 2010-09-24 | 2012-03-29 | International Aids Vaccine Initiative | Novel hiv-1 broadly neutralizing antibodies |
| EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
| US10040826B2 (en) | 2011-07-05 | 2018-08-07 | Duke University | Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens |
| US8791108B2 (en) * | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US20140348865A1 (en) | 2011-09-12 | 2014-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. | Immunogens based on an hiv-1 v1v2 site-of-vulnerability |
| EP2763699A4 (en) * | 2011-10-03 | 2015-05-20 | Univ Duke | VACCINE |
| EP2788026A4 (en) | 2011-12-05 | 2015-08-05 | Univ Duke | V1V2 IMMUNOGENIC |
| CN104271597B (zh) | 2011-12-08 | 2018-05-25 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
| US20150044137A1 (en) * | 2012-03-23 | 2015-02-12 | The United States of America, as represented by the Secretary, Dep. of Health Care Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
| WO2014134547A1 (en) * | 2013-02-28 | 2014-09-04 | Therabiol, Inc. | Hiv antigens and antibodies |
| EP3010549A4 (en) * | 2013-06-17 | 2017-03-15 | Emory University | Pathogen binding agents conjugated to radioisotopes and uses in imaging and therapeutic applications |
| WO2015048517A1 (en) * | 2013-09-28 | 2015-04-02 | Duke University | Escape mutants |
| WO2015127108A1 (en) * | 2014-02-19 | 2015-08-27 | Duke University | Trimeric hiv-1 envelopes compositions and uses thereof |
| US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| SI3166607T1 (sl) | 2014-07-11 | 2023-01-31 | Gilead Sciences, Inc. | Modulatorji toličnih receptorjev za zdravljenje HIV-a |
| CN110305133A (zh) | 2014-09-16 | 2019-10-08 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
| WO2016054023A1 (en) * | 2014-09-29 | 2016-04-07 | Duke University | Hiv-1 antibodies and uses thereof (adcc and bispecific abs) |
| US20180263985A1 (en) | 2015-09-15 | 2018-09-20 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| ES2768957T3 (es) | 2015-09-24 | 2020-06-24 | Abvitro Llc | Composiciones de anticuerpos contra el VIH y métodos de uso |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ, インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| CN107022027B (zh) * | 2016-02-02 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| CN107033241B (zh) * | 2016-02-03 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
| JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv gp120およびcd3を標的とする多重特異性抗体 |
| WO2018237357A1 (en) * | 2017-06-22 | 2018-12-27 | University Of Maryland, Baltimore | HIV-LARGE SPECTRUM HIV NEUTRALIZATION ANTIBODIES AGAINST HIV |
| IL317993B2 (en) | 2018-07-03 | 2025-11-01 | Gilead Sciences Inc | Antibodies directed against HIV gp120 and methods of use |
| US12365722B2 (en) | 2018-10-19 | 2025-07-22 | University Of Maryland, College Park | Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope |
| CA3120324A1 (en) * | 2018-12-04 | 2020-06-11 | The Rockefeller University | Hiv vaccine immunogens |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| US20230134571A1 (en) * | 2019-10-29 | 2023-05-04 | International Aids Vaccine Initiative | Engineered antibodies to hiv env |
| US20210277093A1 (en) * | 2020-03-09 | 2021-09-09 | Adma Biologics, Inc. | Immunotherapeutic compositions and methods of production for coronavirus |
| JP7518286B2 (ja) | 2020-08-25 | 2024-07-17 | ギリアード サイエンシーズ, インコーポレイテッド | Hivを標的とする多重特異性抗原結合分子及び使用方法 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022162009A1 (en) | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
| WO2022161597A1 (en) * | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
| US20240181051A1 (en) * | 2021-04-19 | 2024-06-06 | The Wistar Institute Of Anatomy And Biology | Sialydase linked hiv antibodies and methods of use |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2026039311A1 (en) | 2024-08-10 | 2026-02-19 | Vectorgen | Lentiviral vector for treating human immunodeficiency virus infection |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| AU8295491A (en) | 1990-06-29 | 1992-01-23 | Biosource Technologies Incorporated | Melanin production by transformed microorganisms |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| AU4289496A (en) | 1994-12-02 | 1996-06-19 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| AU2004204462B2 (en) | 2003-01-09 | 2012-03-08 | Macrogenics, Inc. | Dual expression vector system for antibody expression in bacterial and mammalian cells |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| US20070292390A1 (en) * | 2004-10-29 | 2007-12-20 | Dimitrov Dimiter S | Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies |
| CA3201524C (en) * | 2010-08-31 | 2026-01-13 | International Aids Vaccine Initiative | Human immunodeficiency virus (hiv)-neutralizing antibodies |
-
2010
- 2010-03-01 SI SI201032049T patent/SI3260136T1/sl unknown
- 2010-03-17 US US12/726,245 patent/US9051362B2/en active Active
- 2010-03-17 EP EP18207707.3A patent/EP3542817B1/en active Active
- 2010-03-17 DK DK10722810.8T patent/DK2408476T3/en active
- 2010-03-17 EP EP17194834.2A patent/EP3323427B1/en active Active
- 2010-03-17 PL PL17194834T patent/PL3323427T3/pl unknown
- 2010-03-17 EP EP10722810.8A patent/EP2408476B1/en active Active
- 2010-03-17 SM SM20180016T patent/SMT201800016T1/it unknown
- 2010-03-17 HU HUE10722810A patent/HUE036031T2/hu unknown
- 2010-03-17 PL PL10722810T patent/PL2408476T3/pl unknown
- 2010-03-17 PL PL17173548T patent/PL3260136T3/pl unknown
- 2010-03-17 PT PT182077073T patent/PT3542817T/pt unknown
- 2010-03-17 AU AU2010226668A patent/AU2010226668B2/en active Active
- 2010-03-17 PL PL18207707.3T patent/PL3542817T3/pl unknown
- 2010-03-17 HR HRP20180027TT patent/HRP20180027T1/hr unknown
- 2010-03-17 EP EP17173548.3A patent/EP3260136B1/en active Active
- 2010-03-17 WO PCT/US2010/027695 patent/WO2010107939A2/en not_active Ceased
- 2010-03-17 SI SI201031616T patent/SI2408476T1/en unknown
- 2010-03-17 SI SI201032062T patent/SI3323427T1/sl unknown
- 2010-03-17 ES ES17173548T patent/ES2848555T3/es active Active
- 2010-03-17 ES ES17194834T patent/ES2848203T3/es active Active
- 2010-03-17 EP EP22171792.9A patent/EP4085925A1/en active Pending
- 2010-03-17 ES ES18207707T patent/ES2916404T3/es active Active
- 2010-03-17 PT PT171735483T patent/PT3260136T/pt unknown
- 2010-03-17 SI SI201032112T patent/SI3542817T1/sl unknown
- 2010-03-17 PT PT171948342T patent/PT3323427T/pt unknown
- 2010-03-17 CA CA2980883A patent/CA2980883C/en active Active
- 2010-03-17 CA CA2755821A patent/CA2755821C/en active Active
- 2010-03-17 NO NO10722810A patent/NO2408476T3/no unknown
- 2010-03-17 PT PT107228108T patent/PT2408476T/pt unknown
- 2010-03-17 ES ES10722810.8T patent/ES2656234T3/es active Active
- 2010-03-17 LT LTEP10722810.8T patent/LT2408476T/lt unknown
-
2015
- 2015-04-21 US US14/692,483 patent/US9920111B2/en active Active
- 2015-10-01 AU AU2015234345A patent/AU2015234345C1/en active Active
-
2017
- 2017-11-20 AU AU2017264985A patent/AU2017264985B2/en active Active
-
2018
- 2018-01-15 CY CY20181100043T patent/CY1121323T1/el unknown
- 2018-03-12 US US15/918,343 patent/US10239934B2/en active Active
-
2019
- 2019-02-14 US US16/275,936 patent/US10407493B2/en active Active
- 2019-07-17 US US16/513,859 patent/US10865234B2/en active Active
-
2020
- 2020-07-30 AU AU2020210242A patent/AU2020210242B2/en active Active
- 2020-10-28 US US17/082,322 patent/US11584789B2/en active Active
-
2023
- 2023-01-06 US US18/150,957 patent/US12018067B2/en active Active
- 2023-06-26 AU AU2023204017A patent/AU2023204017B2/en active Active
-
2024
- 2024-06-05 US US18/734,520 patent/US12312396B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3542817T3 (pl) | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) | |
| PL3556396T3 (pl) | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) | |
| AU2016202543A1 (en) | Human immunodeficiency virus (hiv)-neutralizing antibodies | |
| IL276182A (en) | Neutralizing antibodies against the human immunodeficiency virus and methods of using them | |
| DK3329772T3 (da) | Dobbeltvektor til inhibering af human immundefektvirus | |
| IL239023A0 (en) | Neutralizing antibodies to influenza viruses | |
| ZA201202116B (en) | Neutralizing antibodies to hiv-1 and their use | |
| PL2908912T3 (pl) | Szeroko neutralizujące przeciwciała anty-hiv | |
| DK3494972T3 (da) | Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion | |
| DK3335728T3 (da) | Biokemisk stabiliseret hiv-1 env-trimervaccine | |
| CR20130228A (es) | Anticuerpos neutralizadores anti-ccl20 | |
| CO6811814A2 (es) | Vacuna de virus dengue inactivado | |
| EP2653091A4 (en) | scanning endoscope | |
| BRPI1013966A2 (pt) | microensaio de esterilidade rápida. | |
| EP2635300A4 (en) | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV) | |
| CU24112B1 (es) | Antígenos vacunales quiméricos contra el virus de la hepatitis c | |
| WO2012139097A3 (en) | Method of inducing neutralizing antibodies to human immunodeficiency virus | |
| BR112013008078A2 (pt) | tratamentos de infecção por vírus da hepatite c | |
| PT2643460T (pt) | Métodos, composições e kits para determinação do virus da imunodeficiência humana (vih) | |
| FI20075028L (fi) | Menetelmä ihmisen immuunikatoviruksen havaitsemiseksi | |
| BR112012030808A2 (pt) | ensaio de vírus da hepatite c de multilinhagem rápido | |
| ES1075148U8 (es) | Dispensador de láminas desechables. | |
| HK1178550A (en) | Human group p immunodeficiency virus and uses thereof |